Free cash flow generation remains inconsistent, highlighted by a sharp divergence in 2025Q3 where net income was negative $34 million while operating cash flow reached $219 million.
| Cash from Operations | 577M | 560M | 541M | 271M | 452M | 483M | -41M | 224.1M | 487.3M | 173.8M | 155.9M |
| Operating CF Margin % | - | 11.88% | 12.19% | 6.14% | 10.25% | 10.14% | -1.25% | 7.3% | 15.89% | 6.02% | 5.35% |
| Operating CF Growth % | 439.7% | 3.51% | 99.63% | -40.04% | -6.42% | 1278.05% | -118.3% | -54.01% | 180.38% | 11.48% | - |
| Net Income | -242M | -232M | 338M | -1.23B | -78M | -472M | -574M | 67.9M | 86.5M | -310.7M | -47.9M |
| Depreciation & Amortization | 691M | 680M | 662M | 694M | 682M | 716M | 517M | 314.5M | 296M | 318.4M | 254.4M |
| Stock-Based Compensation | 74M | 68M | 55M | 46M | 59M | 66M | 47M | 49.4M | 26M | 25M | 20.4M |
| Deferred Taxes | -134M | -134M | -112M | -80M | -57M | -154M | -114M | 100K | -60.7M | -13.4M | -5.9M |
| Other Non-Cash Items | 104M | 79M | -551M | 1.14B | 308M | 414M | -86M | 19.9M | 168.7M | 101M | 104.3M |
| Working Capital Changes | 40M | 99M | 149M | -300M | -462M | -87M | 169M | -227.7M | -29.2M | 53.5M | -169.4M |
| Change in Receivables | 0 | -12M | 12M | -40M | 14M | -3M | 24M | -172.4M | -122M | 48.4M | -80.7M |
| Change in Inventory | 0 | -57M | 44M | -160M | -269M | 27M | -95M | -33.1M | -20.1M | -39M | -89.1M |
| Change in Payables | 0 | 147M | 82M | -94M | -98M | -120M | 362M | -29.2M | 116.1M | -8.4M | 37.1M |
| Cash from Investing | -281M | -279M | 1.16B | -169M | -179M | -530M | -4.78B | -234.8M | -127M | -964.6M | -182.1M |
| Capital Expenditures | -262M | -276M | -147M | -140M | -184M | -197M | -310.9M | -197.4M | -134.5M | -98.6M | -110.3M |
| CapEx % of Revenue | 5.35% | 5.85% | 3.31% | 3.17% | 4.17% | 4.14% | 9.5% | 6.43% | 4.39% | 3.41% | 3.79% |
| Acquisitions | -7M | 0 | 1.32B | -19M | 13M | -342M | -4.57B | -32.8M | 9.4M | -882.1M | -45M |
| Investments | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -12M | -3M | -14M | -10M | -8M | 9M | 169.2M | -4.6M | -1.9M | 16.1M | -26.8M |
| Cash from Financing | -392M | -275M | -1.49B | -83M | -549M | 210M | 4.95B | -304.8M | -35.2M | 847.5M | -149.6M |
| Debt Issued (Net) | -72M | -563M | -1.48B | -77M | -517M | 177M | 3.85B | -121M | 2.49B | 0 | 0 |
| Equity Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 1.22B | 0 | 1.66B | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -320M | 288M | -17M | -6M | -32M | 33M | -118.1M | -183.8M | -4.19B | 847.5M | -149.6M |
| Net Change in Cash | -59M | 77M | 116M | 7M | -293M | 132M | 160.3M | -332.4M | 354.1M | 64.6M | -201.8M |
| Free Cash Flow | 315M | 284M | 394M | 117M | 268M | 286M | -351.9M | 26.7M | 352.8M | 75.2M | 45.6M |
| FCF Margin % | 6.44% | 6.02% | 8.88% | 2.65% | 6.08% | 6% | -10.75% | 0.87% | 11.5% | 2.6% | 1.57% |
| FCF Growth % | -7.62% | -27.92% | 236.75% | -56.34% | -6.29% | 181.27% | -1417.98% | -92.43% | 369.15% | 64.91% | - |
| FCF per Share | 0.62 | 0.57 | 0.79 | 0.24 | 0.55 | 0.59 | -0.80 | 0.07 | 1.12 | 0.21 | 0.13 |
| FCF Conversion (FCF/Net Income) | -1.30x | -2.41x | 1.60x | -0.22x | -5.79x | -1.00x | 0.07x | 3.30x | 5.63x | -0.56x | -3.25x |
| Interest Paid | 0 | 0 | 0 | 379M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
High debt leverage sensitivity
Based on reported financial statements, the persistent divergence between net income and operating cash flow, exemplified by the 2025Q3 period where net income was negative $34 million while operating cash flow reached $219 million, suggests that non-cash charges significantly distort the company's true earnings quality.
The substantial gap between GAAP net income and operating cash flow appears primarily driven by heavy amortization of intangible assets from past acquisitions. Investors should monitor this disconnect, as it implies that reported net income is a poor proxy for the actual cash-generating capacity of the underlying business.
As reported in quarterly filings, Elanco's free cash flow trajectory remains highly erratic, swinging from a negative $69 million in 2025Q1 to a positive $180 million in 2025Q2, which indicates that the company's ability to generate sustainable cash is currently tied to volatile working capital movements.
The lack of a consistent free cash flow trend suggests that operational cash generation is not yet decoupled from seasonal inventory and receivable fluctuations. This volatility warrants further investigation into whether the company can achieve stable cash conversion as it integrates its recent portfolio divestitures.
According to recent SEC filings, working capital changes have been a primary driver of cash flow variability, with a notable $225 million inflow in 2025Q4 contrasting sharply with a $237 million outflow in 2025Q3, highlighting the company's sensitivity to inventory and distributor payment cycles.
These significant quarter-over-quarter swings in working capital suggest that the company may be utilizing aggressive channel management to manage liquidity. Analysts should scrutinize whether these shifts represent genuine operational efficiency or merely temporary timing differences in the collection of receivables and inventory management.
Based on the provided data, Elanco's capital expenditure as a percentage of revenue has fluctuated between 2.0% and 8.1% over the last ten quarters, suggesting that the company maintains a high level of capital intensity to support its extensive manufacturing footprint and ongoing product innovation pipeline.
The persistent need for capital investment appears to be a structural requirement for maintaining the company's complex manufacturing and distribution infrastructure. This level of capital intensity may continue to constrain free cash flow, particularly if competitive pressures necessitate further investment in R&D and production capacity.
Quick answers to the most common questions about buying ELAN stock.
Elanco Animal Health Incorporated (ELAN) generated $560.0M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Elanco Animal Health Incorporated (ELAN) generated $284.0M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
Elanco Animal Health Incorporated (ELAN) spent $276.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.